Lisanti Capital Growth LLC Makes New $1.34 Million Investment in Guardant Health, Inc. (NASDAQ:GH)

Lisanti Capital Growth LLC acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 31,380 shares of the company's stock, valued at approximately $1,337,000.

A number of other large investors have also added to or reduced their stakes in GH. Handelsbanken Fonder AB raised its position in shares of Guardant Health by 6.6% in the 4th quarter. Handelsbanken Fonder AB now owns 28,941 shares of the company's stock valued at $884,000 after purchasing an additional 1,800 shares during the last quarter. Y Intercept Hong Kong Ltd increased its holdings in shares of Guardant Health by 15.6% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 13,799 shares of the company's stock valued at $422,000 after purchasing an additional 1,863 shares during the period. Jones Financial Companies Lllp boosted its position in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after buying an additional 817 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in Guardant Health in the 4th quarter worth approximately $43,000. Finally, Charles Schwab Investment Management Inc. raised its position in Guardant Health by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,016,533 shares of the company's stock worth $31,055,000 after buying an additional 13,395 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on GH. Canaccord Genuity Group raised their target price on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Piper Sandler reissued an "overweight" rating and issued a $60.00 price objective (up previously from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. Scotiabank restated an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. UBS Group lifted their price target on Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Finally, Stephens restated an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty-one analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $53.76.

Insider Transactions at Guardant Health

In related news, Director Musa Tariq sold 3,213 shares of the stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $49.47, for a total transaction of $158,947.11. Following the completion of the transaction, the director owned 7,190 shares of the company's stock, valued at approximately $355,689.30. This trade represents a 30.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Myrtle S. Potter sold 2,626 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $49.70, for a total value of $130,512.20. Following the transaction, the director owned 18,180 shares in the company, valued at $903,546. This trade represents a 12.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 242,274 shares of company stock worth $11,992,589 in the last 90 days. Insiders own 6.10% of the company's stock.

Guardant Health Trading Down 2.2%

Guardant Health stock traded down $1.13 during midday trading on Tuesday, hitting $50.92. 885,632 shares of the stock were exchanged, compared to its average volume of 2,145,228. The stock has a market capitalization of $6.31 billion, a price-to-earnings ratio of -15.02 and a beta of 1.38. The stock's 50-day simple moving average is $45.13 and its 200 day simple moving average is $42.73. Guardant Health, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $53.42.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The firm had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 53.82%. The firm's quarterly revenue was up 20.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.46) earnings per share. Equities analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.